MAPT and Alzheimer disease: Core 2 biomarkers, such as MTBR-tau243, p-tau205 non-phosphorylated mid-region tau fragments, and au PET, become abnormal later in the AD evolution and inform the short-term progression risk in people without symptoms [14].